New video from Crystec highlights mSAS technology

Published: 9-Aug-2017
Manufacturing

mSAS particle engineering versus conventional micronisation


The video is a visual demonstration of the advantages that Crystec’s mSAS (modified supercritical antisolvent) platform has compared with conventional technologies, and the impact that such processing can have on the ease of subsequent manufacturing, as well as product performance.


For more information on how mSAS can accelerate development and enhance the performance of medicines, please visit www.crystecpharma.com.

  • Companies:
  • Crystec Pharma
See more

You may also like

Distribution

Manufacturing Chemist LIVE 2022 in review (part II)

Read more
Taking a front row seat during the two-day pharmaceutical conference in Birmingham, UK, Dr Kevin Robinson reports on what’s new, emerging and exciting in the world of drug delivery and beyond

Trending Articles

  1. Transforming healthcare with patient centricity In this opinion article, John Kytariolos, Head of Clinical and Scientific Affairs at Adragos Pharma, discusses patient-centric dosage forms, their properties and the impact they’re having on the pharmaceutical industry
  2. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the vaccine candidate drug substance commencing late in the third quarter of 2020
  3. ISPE announces 2024 Facility of the Year Awards category winners The awards programme recognises pharmaceutical companies that are the 'best' in the industry for innovation, operations, digitalisation, supply chain and social impact
  4. Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for successful market entry from the early stages of development, reports Frederick Duynslaeger, Senior CMC Writer at Ardena
  5. etherna appoints Shelly West as Business Development Director, US Shelly arrives from Cellpoint Biosciences and will be in charge of expanding etherna's US customer base

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

You may also like

Distribution

Manufacturing Chemist LIVE 2022 in review (part II)

Taking a front row seat during the two-day pharmaceutical conference in Birmingham, UK, Dr Kevin Robinson reports on what’s new, emerging and exciting in the world of drug delivery and beyond
Manufacturing

Crystec wins Contract Services and Outsourcing Award at CPhI Awards

Crystec are delighted to have been awarded the CPhI Excellence in Pharma Award for Contract Services and Outsourcing
Manufacturing

WuXi AppTec peptide facility receives PMDA approval

The company's Changzhou oligonucleotide API manufacturing site was approved by Japan's Pharmaceuticals and Medical Devices Agency
Manufacturing

Ardena's nanomedicines facility marks expansion with first GMP approval

The EUR €20m expansion to the nanomedicines facility at Pivot Park has achieved operational status by the Dutch Healthcare Authority
Manufacturing

ACG awarded ‘Great Place To Work’ certification for a fourth consecutive year

The award recognises employers that create an outstanding experience for employees
Manufacturing

Transforming healthcare with patient centricity

In this opinion article, John Kytariolos, Head of Clinical and Scientific Affairs at Adragos Pharma, discusses patient-centric dosage forms, their properties and the impact they’re having on the pharmaceutical industry
Manufacturing

Medincell collaborates with AbbVie to develop next-generation long-acting injectable therapies

The partnership will focus on the development and commercialisation of six long-acting injectable therapies across various therapeutic areas
Subscribe now